Fludarabine add-on therapy in interferon-beta-treated patients with multiple sclerosis experiencing breakthrough disease

BACKGROUND: Patients with relapsing–remitting multiple sclerosis (RRMS) may experience breakthrough disease despite effective interferon beta (IFNβ) therapy. Fludarabine (FLU) is a chemotherapeutic agent used in lymphoproliferative disorders that may be synergistic when combined with immunomodulator...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Ther Adv Neurol Disord
Hlavní autoři: Greenberg, Steven J., Zivadinov, Robert, Lee-Kwen, Peterkin, Sharma, Jitendra, Planter, Margaret, Umhauer, Margaret, Glenister, Norman, Bakshi, Rohit
Médium: Artigo
Jazyk:Inglês
Vydáno: SAGE Publications 2016
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4784253/
https://ncbi.nlm.nih.gov/pubmed/27006698
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756285615626049
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky